Corcept Therapeutics announced results from its DAZALS study, a randomized, double-blind, placebo-controlled Phase 2 trial evaluating dazucorilant in patients with Amyotrophic Lateral Sclerosis (ALS). The study did not meet its primary endpoint, which was the change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R) score.
Despite missing the primary functional endpoint, an exploratory analysis revealed a significant survival signal during the 24-week study period. No deaths were observed in the 300 mg dazucorilant arm (0/83 patients), compared to five deaths in the placebo group (5/82 patients), with a p-value of 0.02.
The open-label, long-term extension study for dazucorilant will continue, with overall survival to be assessed in March 2025. Dazucorilant has been granted Fast Track Designation by the U.S. Food and Drug Administration, indicating its potential to address an unmet medical need.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.